ChemoCentryx to Present at Two Upcoming Investor Conferences
November 19 2020 - 8:30AM
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J.
Schall, Ph.D., President and Chief Executive Officer, will present
at two upcoming investor conferences:
Piper Sandler 32nd Annual
Virtual Healthcare ConferenceOn-demand
presentation available beginning Monday, November 23 at 10:00
a.m. Eastern Time
Evercore ISI 3rd
Annual HealthCONx
ConferenceThursday, December 3, 2020 at 1:25 p.m.
Eastern Time
A live audio webcast of the Evercore presentation and the
on-demand Piper Sandler presentation can be accessed through the
Investors section of the Company's website at www.ChemoCentryx.com.
Both webcasts will be available on the Company's website for two
weeks following the respective presentation dates.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new
medications for inflammatory and autoimmune diseases and
cancer. ChemoCentryx targets the chemokine and
chemoattractant systems to discover, develop and commercialize
orally administered therapies. ChemoCentryx’s lead drug candidate,
avacopan (CCX168), successfully completed a pivotal Phase III trial
in ANCA-associated vasculitis and a New Drug Application is under
review by the U.S. Food and Drug Administration, along with a
Marketing Authorization Application by the European Medicines
Agency. Avacopan is also in late stage clinical development for the
treatment of Hidradenitis Suppurativa and C3 glomerulopathy
(C3G).
ChemoCentryx also has early stage drug candidates that
target chemoattractant receptors in other inflammatory and
autoimmune diseases and in cancer.
Contacts:
Susan M. KanayaExecutive Vice President,Chief
Financial and Administrative Officerinvestor@chemocentryx.com
Media:Stephanie Tomei408.234.1279media@chemocentryx.com
Investors:Lee Roth, Burns
McClellan212.213.0006lroth@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Apr 2024 to May 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From May 2023 to May 2024